Multicenter, single group study of aripiprazole efficacy and safety in the acute psychosis treatment of schizophrenia, schizophreniform disorder and schizoaffective disorder
Phase of Trial: Phase IV
Latest Information Update: 19 Sep 2016
At a glance
- Drugs Aripiprazole (Primary)
- Indications Psychotic disorders; Schizoaffective disorder; Schizophrenia
- Focus Therapeutic Use
- Acronyms APLUS
- Sponsors Otsuka Pharmaceutical
- 31 Aug 2018 Biomarkers information updated
- 15 Dec 2009 Actual end date (Oct 2007) added as reported by ClinicalTrials.gov.
- 15 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.